Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Lancet (London, England)
|
August 27, 1983
Bone-marrow transplantation for inborn error of phagocytic cells associated with defective adherence, chemotaxis, and oxidative response during opsonised particle phagocytosis
A Fischer, P H Trung, B Descamps-Latscha, et al.
The Pediatric Infectious Disease Journal
|
June 1, 1994
Severe acute paracoccidioidomycosis in children
G Benard, N M Orii, H H Marques, et al.
European Journal of Cancer
|
April 1, 1977
An effect human leukaemic cell line: Reh
C Rosenfeld, A Goutner, A M Venuat, et al.
Blood
|
October 27, 1998
Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome
M Benkerrou, J P Jais, V Leblond, et al.
Methods (San Diego, Calif.)
|
January 1, 1997
Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity
D Emilie, W Zou, R Fior, et al.
The Journal of Biological Chemistry
|
March 31, 1995
Recombinant soluble trimeric CD40 ligand is biologically active
G J Mazzei, M D Edgerton, C Losberger, et al.
The American Journal of Tropical Medicine and Hygiene
|
August 1, 1995
Responses of T and B lymphocytes to a Paracoccidioides brasiliensis cell wall extract in healthy sensitized and nonsensitized subjects
G Benard, A Durandy, C M Assis, et al.
Clinical Immunology (Orlando, Fla.)
|
December 9, 2000
Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome
Y Minegishi, A Lavoie, C Cunningham-Rundles, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 15, 1997
Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression
A Durandy, C Hivroz, F Mazerolles, et al.
Blood
|
March 10, 2001
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
E Haddad, S Paczesny, V Leblond, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Lancet (London, England)
|
August 27, 1983
Bone-marrow transplantation for inborn error of phagocytic cells associated with defective adherence, chemotaxis, and oxidative response during opsonised particle phagocytosis
A Fischer, P H Trung, B Descamps-Latscha, et al.
The Pediatric Infectious Disease Journal
|
June 1, 1994
Severe acute paracoccidioidomycosis in children
G Benard, N M Orii, H H Marques, et al.
European Journal of Cancer
|
April 1, 1977
An effect human leukaemic cell line: Reh
C Rosenfeld, A Goutner, A M Venuat, et al.
Blood
|
October 27, 1998
Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome
M Benkerrou, J P Jais, V Leblond, et al.
Methods (San Diego, Calif.)
|
January 1, 1997
Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity
D Emilie, W Zou, R Fior, et al.
The Journal of Biological Chemistry
|
March 31, 1995
Recombinant soluble trimeric CD40 ligand is biologically active
G J Mazzei, M D Edgerton, C Losberger, et al.
The American Journal of Tropical Medicine and Hygiene
|
August 1, 1995
Responses of T and B lymphocytes to a Paracoccidioides brasiliensis cell wall extract in healthy sensitized and nonsensitized subjects
G Benard, A Durandy, C M Assis, et al.
Clinical Immunology (Orlando, Fla.)
|
December 9, 2000
Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome
Y Minegishi, A Lavoie, C Cunningham-Rundles, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 15, 1997
Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression
A Durandy, C Hivroz, F Mazerolles, et al.
Blood
|
March 10, 2001
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial
E Haddad, S Paczesny, V Leblond, et al.
Page
of 13